# A First-in-Man Study of the Firesorb BVS (FUTURE-I)

> **NCT02659254** · NA · COMPLETED · sponsor: **Shanghai MicroPort Medical (Group) Co., Ltd.** · enrollment: 45 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** Sirolimus Target Eluting Bioresorbable Vascular Scaffold

## Key facts

- **NCT ID:** NCT02659254
- **Lead sponsor:** Shanghai MicroPort Medical (Group) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-05
- **Final completion:** 2021-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02659254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02659254, "A First-in-Man Study of the Firesorb BVS (FUTURE-I)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02659254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*